No Data
Express News | Cantor Fitzgerald Reiterates Overweight on Tourmaline Bio, Maintains $25 Price Target
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $49
Strategic Developments in Tourmaline Bio's Cardiovascular Programs Drive Buy Rating
Tourmaline Bio Unveils Clinical Progress and New Indication
Tourmaline Bio Highlights Cardiovascular Inflammation Focus And Announces Key Clinical And Strategic Updates At Investor Day; Phase 2 TRANQUILITY Trial Surpasses Enrollment Target, With 143 Total Patients Enrolled
Trytosaveabit : Larry Fink is a terrible awful person! Sad part it’s hard to trade any ticker that he don’t have a part of! He has been on a buying spree! I’ve seen at least 25 in last 24 hours! Prolly more that he has been buying!